Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • In Brief
  • Published:

Epigenetics

Targeting chromatin regulation in PDAC

Nature Reviews Drug Discovery volume 14, page 750 (2015)Cite this article

Subjects

Chromatin remodelling and modification pathways are emerging as promising anticancer targets. Mazur et al. investigate the potential of targeting the bromodomain and extra-terminal (BET) protein family of chromatin regulators in pancreatic ductal adenocarcinoma (PDAC). The BET inhibitor, JQ1, reduced tumour volume, decreased proliferation and improved survival in mouse models of PDAC. Combination of JQ1 with the small-molecule HDAC inhibitor, SAHA, was synergistic in the PDAC model, without evidence of tumour relapse or metastasis.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on SpringerLink
  • Instant access to the full article PDF.

USD 39.95

Prices may be subject to local taxes which are calculated during checkout

References

  1. Mazur, P. et al. Combined inhibition of BET family proteins and histone deacetylases as a potential epigenetics-based therapy for pancreatic ductal adenocarcinoma. Nat. Med. http://dx.doi.org/10.1038/nm.3952 (2015)

Download references

Authors
  1. Sarah Crunkhorn
    View author publications

    Search author on:PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Crunkhorn, S. Targeting chromatin regulation in PDAC. Nat Rev Drug Discov 14, 750 (2015). https://doi.org/10.1038/nrd4776

Download citation

  • Published:

  • Issue date:

  • DOI: https://doi.org/10.1038/nrd4776

Search

Advanced search

Quick links

Nature Briefing: Translational Research

Sign up for the Nature Briefing: Translational Research newsletter — top stories in biotechnology, drug discovery and pharma.

Get what matters in translational research, free to your inbox weekly. Sign up for Nature Briefing: Translational Research